16 September 2026 editorial review · Trial
CKM for safer SGLT2 inhibitor use in type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Corrected claim that trial tests monitor reducing ketones; registered comparisons concern sotagliflozin doses and insulin-delivery groups.
Registry: NCT07211802. Registered endpoint checked: BHB Time Above 0.6mmol/L - 200mg (6 weeks); BHB Time Above 0.6mmol/L - 400mg (6 weeks). Eligibility check: Registry age 18 Years to not specified; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.